Neovascular AMD (nAMD) is a condition that mainly affects elderly populations and can cause vision impairment and even total vision loss. This condition occurs when vascular endothelial growth factor (VEGF) causes abnormal blood vessels to develop in the back of the eye.

This condition is characterized by three different stages. Early stages of nAMD may not show any symptoms, making it harder to diagnose and treat when the condition first appears. Later stages, however, present more obvious symptoms as the disease progresses, such as drastic vision changes, difficulties seeing at night, blank spots, and blurriness.

Real-world nAMD data is vital in treating patients with this condition. With Verana Health’s Qdata nAMD, researchers and clinicians can work to better understand the patient journey, disease progression and anti-VEGF treatment efficacy.

Verana Health is the exclusive real-world data and analytics partner of the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight). Both structured and unstructured data from EHRs across the US are curated to generate Qdata nAMD, a research-ready module to generate real-world evidence for life sciences companies.